Stay updated on Nivolumab & Brentuximab in Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab & Brentuximab in Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab & Brentuximab in Lymphoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study results related to the safety and effectiveness of Nivolumab in combination with Brentuximab Vedotin for treating certain subtypes of non-Hodgkin lymphomas with CD30 expression.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:35.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide a detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments. It also includes a link for more information about BMS clinical trial participation and specifies inclusion criteria for various types of relapsed/refractory lymphomas.
    Difference
    11%
    Check dated 2024-05-22T20:33:39.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:40:22.000Z thumbnail image

Stay in the know with updates to Nivolumab & Brentuximab in Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab & Brentuximab in Lymphoma Clinical Trial page.